History of ACE Pharmaceuticals

Since the establishment in 1990 many developments have took place, that formed the organisation like it is today. It is our pleasure to share some of these developments with you.

2016 Nomination “Flevopenningen” award for Innovation, Province of Flevoland, the Netherlands
2016 First submission of a dossier with EMA (European Medicines Agency) for a centralised procedure for licensing of ELMISOL® (Levamisole HCl) as an Orphan Drug
2015 ALBINO-project selected in Horizon 2020
2015 (Third) Orphan Drug Designation for Allopurinol (Allokid = Allopurinol 100 mg, pfi)
2015 Malacef® included on Tableau d’honneur (Honours List) of the independent French professional journal Prescrire, for the (urgent) treatment of severe malaria
2015 ACE winner Humanimal – One Health Innovation Challenge with XCYST®
2013 New pharmaceutical complex in Zeewolde, the Netherlands
2011 Start of ACE Apotheek (supply of unlicensed medicines to pharmacies)
2010 Sale of RP Zeewolde BV
2008 Sale of ACE Veterinary Products BV
2007 (Second) Orphan Drug Designation for Artesunate powder for injection (Malacef®)
2007 Winner Entrepeneur 2006, Zeewolde, the Netherlands
2007 Winner “Flevopenningen” award, Province of Flevoland, the Netherlands
2005 (First) Orphan Drug Designation for Levamisole HCl (ELMISOL®)
2001 New strategy: focus on (human) Medical Need Products
1996 ACE moves into new, modern factory in Zeewolde, the Netherlands
1993 ACE Pharmaceuticals established in Katwijk, the Netherlands and acquires GMP-license
1990 Establishment of the company in Maarssen, the Netherlands; focus on veterinary medicines